Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Running, not enrolling · Phase 3

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or second androgen receptor-directed therapy \[ARDT\]).

Key facts

Study ID: NCT06691984
Run by: Amgen
People needed: 707
Starts: 2024-12-09
Expected to finish: 2029-07-30
Last updated by the study team: 2026-05-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

Participant has provided informed consent prior to initiation of any study-specific activities/procedures.
Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.
Participant must have histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate. Mixed histologies (eg, adenocarcinoma with neuroendocrine component) are not permitted.
mCRPC with ≥ 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging obtained within 28 days prior to enrollment.
Evidence of progressive disease, defined as 1 or more PCWG3 criteria:
Serum PSA progression defined as 2 consecutive increases in PSA over a previous reference value measured at least 1 week prior. The minimal start value is 2.0 ng/mL.
Soft-tissue progression defined as an increase ≥ 20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions or unequivocal progression of existing non-target lesions.
Progression of bone disease: defined by the appearance of at least 2 new bone lesion(s) by bone scan (as per the 2+2 PCWG3 criteria).
Participants must have had a prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum testosterone (< 50 ng/dL or < 1.7 nmol/L).
Prior progression on at least one ARDT (enzalutamide, abiraterone, apalutamide, darolutamide).
Prior treatment with only one taxane therapy in the mCRPC setting. Note: Prior treatment with docetaxel in the metastatic hormone-sensitive prostate cancer (mHSPC) setting is permitted; however, participants must have also received one, and only one, taxane therapy in the mCRPC setting.
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
Adequate organ function.
Life expectancy of ≥ 12 weeks per the treating physician's assessment.
Key Exclusion Criteria:
Prior \& Concomitant Therapy:
Prior six transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted therapy.
Any anticancer therapy, immunotherapy, or investigational agent within 4 weeks prior to the first dose of study treatment, not including androgen receptor pathway inhibitors (ARPIs) (abiraterone, enzalutamide, darolutamide, apalutamide): minimum washout of 2 weeks prior to the first dose of study treatment and androgen suppression therapy (eg, luteinizing hormone-releasing hormone/gonadotropin-releasing hormone [LHRH/GnRH] analogue [agonist/antagonist]).
Prior Prostate-Specific Membrane Antigen (PSMA) radioligand therapy (RLT) within 3 months of the first dose of study treatment unless participants received < 2 cycles of therapy.
Prior palliative radiotherapy within 2 weeks of first dose of study treatment. Participants must have recovered from all radiation-related toxicities.
Concurrent cytotoxic chemotherapy, ARDT, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy, investigational therapy. Note: Prior treatment with a PARP inhibitor is permitted as long as not within 4 weeks before first dose of study treatment.
Prior radionuclide therapy (Radium-223) within 2 months of first dose of study treatment.
Treatment with live and live-attenuated vaccines within 4 weeks before the first dose of study treatment.
Disease Related:
Participants with a history of central nervous system (CNS) metastasis. Note: Participants with treated, asymptomatic, and clinically stable dural metastases are eligible.

Where it is running

City of Hope National Medical Center — Duarte, California, United States
Providence Saint Jude Medical Center — Fullerton, California, United States
Cedars Sinai Medical Center — Los Angeles, California, United States
University of California Irvine — Orange, California, United States
University of California San Francisco — San Francisco, California, United States
University of Florida, College of Medicine — Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center-Fox Building — Miami, Florida, United States
AdventHealth Orlando — Orlando, Florida, United States
University of Chicago — Chicago, Illinois, United States
Indiana University — Indianapolis, Indiana, United States
University of Louisville Health - James Graham Brown Cancer Center — Louisville, Kentucky, United States
Norton Cancer Institute — Louisville, Kentucky, United States
Massachusetts General Hospital — Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Henry Ford Hospital, Henry Ford Health Systems — Detroit, Michigan, United States
University of Minnesota — Minneapolis, Minnesota, United States
Washington University — St Louis, Missouri, United States
Yale New Haven Hospital — New York, New York, United States
Memorial Sloan Kettering Cancer Center — New York, New York, United States
Montefiore Medical Center — The Bronx, New York, United States
Levine Cancer Institute — Charlotte, North Carolina, United States
Duke University Medical Center Duke Cancer Center — Durham, North Carolina, United States
Sanford Roger Maris Cancer Center — Fargo, North Dakota, United States
University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.